Skip to main content
. 2014 Dec 16;100(3):1088–1096. doi: 10.1210/jc.2014-3586

Table 2.

Risk of Atrial Fibrillation, Coronary Heart Disease, Heart Failure, or a Composite Cardiovascular Disease Measure for a One Unit Higher TSH, FT4, or Total T3

Model No. of Events/No. at Risk TSH, mU/L
Free T4, pmol/L
Total T3, nmol/L
HR 95% CI P Value HR 95% CI P Value HR 95% CI P Value
Atrial fibrillation 812/2673
    Model 1 0.94 0.87–1.01 .09 1.06 1.03–1.10 <.001 0.90 0.70–1.15 .40
    Model 2 0.94 0.87–1.02 .12 1.04 1.01–1.08 .02 0.86 0.67–1.11 .24
Coronary heart disease 786/2215
    Model 1 0.95 0.88–1.03 .20 1.03 0.99–1.06 .13 1.23 0.97–1.56 .09
    Model 2 0.95 0.88–1.02 .15 1.02 0.98–1.05 .28 1.13 0.89–1.45 .31
Heart failure 870/2706
    Model 1 0.95 0.88–1.02 .17 1.05 1.02–1.09 .004 1.07 0.85–1.35 .54
    Model 2 0.94 0.87–1.01 .09 1.04 1.00–1.07 .03 1.04 0.82–1.32 .77
Composite cardiovascular outcome 1128/2073
    Model 1 0.94 0.88–1.00 .05 1.04 1.01–1.07 .008 1.09 0.89–1.33 .43
    Model 2 0.94 0.88–1.00 .04 1.03 1.00–1.06 .02 0.97 0.79–1.19 .78

Model 1 for all outcomes is adjusted for age, sex, race and initiation of thyroid meds (time-varying).

Model 2 for atrial fibrillation additionally adjusted for BMI, hypertension, fasting glucose, current smoking, any alcohol use, valvular disease history, and use of any diuretic or β blocker.

Model 2 for coronary heart disease additionally adjusted for BMI, hypertension, diabetes, current smoking, low-density lipoprotein cholesterol, lipid lowering medication use, and C-reactive protein.

Model 2 for heart failure additionally adjusted for BMI, hypertension, diabetes, current smoking, coronary heart disease, atrial fibrillation, stroke, claudication, any alcohol use, and creatinine (natural log).

Model 2 for composite cardiovascular disease outcome additionally adjusted for BMI, hypertension, diabetes, stroke, claudication, current smoking, C-reactive protein, and creatinine.